Clinical Trials Logo
  1. Home
  2. Tuberculosis
  3. NCT01601275
  4. Details
NCT01601275 Clinical Trial

Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection

Tuberculosis Clinical Trial

Official title:
Prospective Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection Treated at Singapore General Hospital

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01601275
Other study ID # 2005/060/CTBdatabase
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2012
Est. completion date May 2018

Study information
Verified date May 2019
Source Singapore General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective data collection of all patients with microbiologically proven mycobacteria tuberculosis infection treated at Singapore General Hospital.

Description:

Tuberculosis currently infects one third of the world's population and is responsible for killing approximately 2 million individuals annually. This is a major public health concern worldwide, and there has been a huge impetus to implement strategies for better tuberculosis control.

The investigators have established a system to track all patients with microbiologically proven tuberculosis treated at Singapore General Hospital, with vigilant recording and reporting systems, from the first instance when patients were diagnosed to the time they have completed anti-tuberculosis chemotherapy. The investigators endeavour to use this system to improve patient care by adopting patient-supportive approaches that lead to high compliance rates and best possible outcomes of treatment.

Recruitment information / eligibility
Status Completed
Enrollment 4600
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

1) All patients with microbiologically proven mycobacteria tuberculosis infection treated at the Singapore General Hospital.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Singapore Singapore General Hospital Singapore

Sponsors (1)
Lead Sponsor Collaborator
Singapore General Hospital

Country where clinical trial is conducted

Singapore, 

References & Publications (2)

DeAngelis CD, Flanagin A. Tuberculosis--a global problem requiring a global solution. JAMA. 2005 Jun 8;293(22):2793-4. — View Citation

Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005 Jun 8;293(22):2767-75. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Final outcomes of patients who have been diagnosed with microbiologically proven mycobacteria tuberculosis infection at Singapore General Hospital From diagnosis to final outcome
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2